Sort
17,054 grants matching “genome editing”
Nanoparticle-mediated delivery of a base editor for in utero treatment of Canavan Disease
$423,939Aijun Wang · University Of California At Davis · R21 · FY2023 · NS
Unraveling the role of HLA-B51/ERAP1 in Behcet's eye disease
$423,751Johannes Nowatzky · New York University School Of Medicine · R01 · FY2023 · EY
Underlying chromatin architecture defines functionality for CFTR expression
$423,750Martin John Walsh · Icahn School Of Medicine At Mount Sinai · R01 · FY2019 · DK
Unraveling the role of HLA-B51/ERAP1 in Behcet's eye disease
$423,750Johannes Nowatzky · New York University School Of Medicine · R01 · FY2024 · EY
Unraveling the role of HLA-B51/ERAP1 in BehcetâÃâ¬Ãâ¢s eye disease
$423,750Johannes Nowatzky · New York University School Of Medicine · R01 · FY2021 · EY
Underlying chromatin architecture defines functionality for CFTR expression
$423,750Martin John Walsh · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · DK
Genomic organization of long-distance gene regulation
$423,750Matthew Thomas Maurano · New York University School Of Medicine · R35 · FY2020 · GM
Underlying chromatin architecture defines functionality for CFTR expression
$423,750Martin John Walsh · Icahn School Of Medicine At Mount Sinai · R01 · FY2018 · DK
Underlying chromatin architecture defines functionality for CFTR expression
$423,750Martin John Walsh · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · DK
THE ROLE OF AGRIN/LRP4/MUSK/DOK-7 SIGNALING IN DISASSEMBLY OF NEUROMUSCULAR SYNAPSES DURING AGING.
$423,750Steven J Burden · New York University School Of Medicine · R01 · FY2016 · AG
Genomic organization of long-distance gene regulation
$423,750Matthew Thomas Maurano · New York University School Of Medicine · R35 · FY2016 · GM
Underlying chromatin architecture defines functionality for CFTR expression
$423,750Martin John Walsh · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · DK
THE ROLE OF AGRIN/LRP4/MUSK/DOK-7 SIGNALING IN DISASSEMBLY OF NEUROMUSCULAR SYNAPSES DURING AGING.
$423,750Steven J Burden · New York University School Of Medicine · R01 · FY2019 · AG
Genomic organization of long-distance gene regulation
$423,750Matthew Thomas Maurano · New York University School Of Medicine · R35 · FY2019 · GM
THE ROLE OF AGRIN/LRP4/MUSK/DOK-7 SIGNALING IN DISASSEMBLY OF NEUROMUSCULAR SYNAPSES DURING AGING.
$423,750Steven J Burden · New York University School Of Medicine · R01 · FY2017 · AG
THE ROLE OF AGRIN/LRP4/MUSK/DOK-7 SIGNALING IN DISASSEMBLY OF NEUROMUSCULAR SYNAPSES DURING AGING.
$423,750Steven J Burden · New York University School Of Medicine · R01 · FY2015 · AG
Directing the metabolic fate of CAR T cells
$423,662Carl H. June · University Of Pennsylvania · R01 · FY2022 · CA
Identification and validation of molecular markers of piperaquine resistance
$423,595Shannon Takala Harrison · University Of Maryland Baltimore · R01 · FY2018 · AI
In vivo investigation of PKD1 upstream open reading frames as a therapeutic target in autosomal dominant polycystic kidney disease
$423,535Whitney Elise Besse · Yale University · R01 · FY2024 · DK
Novel Interplay of KILN and MKL1 in Vascular Pathophysiology
$423,500Xiaochun Long · Augusta University · R01 · FY2022 · HL
Novel Interplay of KILN and MKL1 in Vascular Pathophysiology
$423,500Xiaochun Long · Augusta University · R01 · FY2020 · HL
Novel Interplay of KILN and MKL1 in Vascular Pathophysiology
$423,500Xiaochun Long · Augusta University · R01 · FY2021 · HL
THE USE OF GENE EDITING IN LIVESTOCK HAS THE POTENTIAL TO IMPROVE DISEASE RESISTANCE, PRODUCTIVITY AND SUSTAINABILITY OF ANIMAL AGRICULTURE. HOWEVER, STAKEHOLDERS SUCH AS FARMERS, REGULATORS AND THE GENERAL PUBLIC HAVE CONCERNS REGARDING THE SAFETY OF THIS TECHNOLOGY IN FOOD ANIMALS. SOME OF THESE CONCERNS INCLUDE THE SPECIFICITY OF GENE EDITING EVENTS (IE IS ONLY THE DESIRED LOCATION BEING MODIFIED) AND THE CONTAINMENT OF GENETICALLY MODIFIED/GENE EDITED ANIMALS TO PREVENT THE UNINTENDED INCORPORATION OF THE GENETIC MODIFICATION INTO DOMESTIC OR WILD ANIMALS. THIS RESEARCH WILL ADDRESS BOTH THESE ISSUES BY USING GENE EDITING TO RENDER MALES STERILE AS A MEANS OF CONTAINMENT WHILE ALSO COLLECTING INFORMATION ON OFF-TARGET EFFECTS OF GENE EDITING TOOLS IN LIVESTOCK FOR REGULATORS TO MAKE INFORMED DECISIONS ON THE SAFETY OF THE TECHNOLOGY.GENE EDITED PIGS WILL BE PRODUCED THAT LACK A KEY COMPONENT REQUIRED FOR THE PRODUCTION OF MALE REPRODUCTIVE HORMONES. WITH REDUCED LEVELS OF MALE REPRODUCTIVE HORMONES, THE DEVELOPMENT OF THE REPRODUCTIVE TRACT OF MALE PIGS WILL BE IMPAIRED AND MALE PIGS WILL BE STERILE. FEMALE PIGS SHOULD REMAIN FERTILE. IN ADDITION, REDUCED LEVELS OF MALE REPRODUCTIVE HORMONES WILL PREVENT THE COMPOUND RESPONSIBLE FOR BOAR TAINT, OR THE STALE URINE/FECAL FLAVOR THAT APPEARS IN THE MEAT OF NON-CASTRATED MALE PIGS BEFORE THEY REACH MARKET WEIGHT, FROM BEING FORMED. THIS HAS THE POTENTIAL TO ABOLISH THE NEEDED AND COMMON PRACTICE OF CASTRATING NEONATAL MALE PIGLETS AS A MEANS TO ELIMINATE BOAR TAINT, A MAJOR BENEFIT TO ANIMAL WELFARE AND PORK PRODUCERS IN THE UNITED STATES. THE RESULTING GENE EDITED PIGS WILL BE FULLY CHARACTERIZED IN TERMS OF THEIR REPRODUCTIVE CAPACITY AS WELL AS BASIC FUNCTIONS SUCH AS GROWTH AND BEHAVIOR AS BROAD INDICATORS OF WELL-BEING OF GENE EDITED ANIMALS. IT IS ANTICIPATED THAT THE PROPOSED GENE EDIT WILL BE COMPATIBLE WITH ORGANISMAL WELL-BEING OF THE ANIMALS AND THAT GENE EDITING TOOLS WILL RESULT IN MODIFICATIONS AT THEDESIRED LOCATION IN THE GENOME WITH FEW OFF-TARGET EVENTS. IF SUCCESSFUL, THIS CONTAINMENT APPROACH CAN EASILY BE APPLIED TO OTHER ANIMAL SPECIES. THIS WORK MOST DIRECTLY ADDRESSES PROGRAM AREA 1 (MANAGEMENT PRACTICES TO MINIMIZE ENVIRONMENTAL RISK OF GE ORGANISMS), NAMELY 1C, THE DEVELOPMENT OR EVALUATION OF EFFECTIVE BIOCONTAINMENT STRATEGIES INCLUDING MOLECULAR AND/OR GENETIC TECHNIQUES.
$423,482University Of California, Davis · · FY2018 · National Institute of Food and Agriculture
Assessing DREAM complex formation and function
$423,381Paul Goetsch · Michigan Technological University · R15 · FY2020 · GM
Genetic and Molecular Basis of Longevity
$423,320Gary B. Ruvkun · Massachusetts General Hospital · R01 · FY2025 · AG